Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIOGEN INC. Director's Dealing 2025

Feb 10, 2025

30291_dirs_2025-02-10_aef88efe-33ba-4554-859e-8bed3c349791.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOGEN INC. (BIIB)
CIK: 0000875045
Period of Report: 2025-02-06

Reporting Person: Gregory Ginger (EVP, Human Resources)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-02-07 Common Stock M 1635 Acquired 15312.1006 Direct
2025-02-07 Common Stock F 480 $141.35 Disposed 14832.1006 Direct
2025-02-07 Common Stock M 1801 Acquired 16633.1006 Direct
2025-02-07 Common Stock F 560 $141.35 Disposed 16073.1006 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2025-02-06 Restricted Stock Unit $0 A 11240 Acquired 2028-02-06 Common Stock (11240) Direct
2025-02-07 Restricted Stock Unit $0 M 1635 Disposed 2026-02-08 Common Stock (1635) Direct
2025-02-07 Restricted Stock Unit $0 M 1801 Disposed 2027-02-07 Common Stock (1801) Direct

Footnotes

F1: Includes 93.3846 shares acquired under the Biogen Inc. employee stock purchase plan on 3/31/2024.

F2: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 6, 2025.

F3: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 02/08/2023.

F4: The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024.